ConductScience.org, home

Paper35543795

Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?

Papp H and 3 others. Geroscience, 2022. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19? Papers, record 35543795. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35543795

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
PubMed
Journal
Geroscience
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.19
iCite
Revised in PubMed
2026-09-27
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Papp HHenriettahttps://orcid.org/0000-0003-3887-5657
2Lanszki ZZsófiahttps://orcid.org/0000-0003-3116-4633
3Keserű GMGyörgy M
4Jakab FFerenchttps://orcid.org/0000-0002-3913-0430

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19 Drug TreatmentMajor topic
Aged
Amides
Humans
Pyrazines
SARS-CoV-2
Treatment Outcome

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129524445Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.Antiviral Res2018https://conductscience.org/library/papers/29524445PubMed
215728892Mechanism of action of T-705 against influenza virus.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/15728892PubMed
332346491Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.Engineering (Beijing)2020https://conductscience.org/library/papers/32346491PubMed
434914868Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.N Engl J Med2022https://conductscience.org/library/papers/34914868PubMed
526798032Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Clin Pharmacokinet2016https://conductscience.org/library/papers/26798032PubMed
634726479An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.Science2021https://conductscience.org/library/papers/34726479PubMed
732536670Uric Acid Elevation by Favipiravir, an Antiviral Drug.Tohoku J Exp Med2020https://conductscience.org/library/papers/32536670PubMed
832377677COVID-19 in older people: a rapid clinical review.Age Ageing2020https://conductscience.org/library/papers/32377677PubMed
915095236Nucleoside analogues and mitochondrial toxicity.Clin Infect Dis2004https://conductscience.org/library/papers/15095236PubMed
1024951535Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.J Antimicrob Chemother2014https://conductscience.org/library/papers/24951535PubMed
1132943628Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.Nat Commun2020https://conductscience.org/library/papers/32943628PubMed
1235740211Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand.Antibiotics (Basel)2022https://conductscience.org/library/papers/35740211PubMed
1333212256Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.Int J Infect Dis2021https://conductscience.org/library/papers/33212256PubMed
1416084170Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?Am J Med2005https://conductscience.org/library/papers/16084170PubMed
1534040117The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.Sci Rep2021https://conductscience.org/library/papers/34040117PubMed
1632097670Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.Pharmacol Ther2020https://conductscience.org/library/papers/32097670PubMed
1732020029Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell Res2020https://conductscience.org/library/papers/32020029PubMed
1834044777Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.BMC Infect Dis2021https://conductscience.org/library/papers/34044777PubMed
1934476717Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary.Geroscience2021https://conductscience.org/library/papers/34476717PubMed
2034539392Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial.Front Pharmacol2021https://conductscience.org/library/papers/34539392PubMed

See all 35 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
39592539Advancements in Antiviral Therapy: Favipiravir Sodium in Nasal Formulation.AAPS PharmSciTech2024https://conductscience.org/library/papers/39592539PubMed
36903575Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population.Molecules2023https://conductscience.org/library/papers/36903575PubMed
36160358Perspective: repurposed drugs for COVID-19.Arch Med Sci2022https://conductscience.org/library/papers/36160358PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35543795

GET https://conductscience.org/api/papers/v1/35543795/references?page=2